drugset / Trial / NCT00503412

Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors

NCT00503412

Phase 1 Completed 6 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Open, non-randomised, radiolabelled, single centre study with a total of six patients with solid metastatic tumors to determine the rates and routes of elimination of 14C-AZD2171 and its metabolites.

Timeline

Start
2005-11
Primary completion
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cediranib Small molecule Oral